



Anticoagulation
FORUM



News from the Anticoagulation Forum
February 2018

In This Issue

Boot Camp Austin * AC Forum Clinical Order Sets * February Webinar: COMPASS Trial
THSNA Summit Hotel Deadline * ThrombosisAdvisorUS



Anticoagulation
FORUM

ANTICOAGULATION



BOOT CAMP



Experience AC Forum Boot Camp April 23-24, 2018 | The Intercontinental, Austin

This compact 2-day meeting covers the essential aspects of anticoagulation, disease state, and drug management. Engaging discussion around quality improvement, new agents and special situations will benefit all practitioners and daily 'chalk talks' will allow for attendee participation to shape the topics. The Transitions of Care Summit includes highlights of innovative programs, patient case studies and ideas for practice improvement in all aspects of patient transition.

Join 10 AC Forum board members along with other expert speakers. See the full [schedule](#), [faculty listing](#) and register at: acforumbootcamp.org.

Approximately 11.25 contact hours of education credit will be offered for Physicians, Nurses and Pharmacists. **Registration is \$399.**

REGISTER 

AC Forum Order Sets

AC Forum has created two new order sets for Atrial Fibrillation and VTE. They can be found in the [Resource Center](#) on our Centers of Excellence site.

PatientOrderSets PATIENT INFORMATION

Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process

Initiation of OAC for Atrial Fibrillation Order Set

For Patients Clinically Unsuitable for DOACs
 Clinician to consider warfarin for the following indications:
 Mechanical valve - warfarin is indicated to decrease the risk of thromboembolic complications
 Rheumatic Mitral stenosis - warfarin is indicated for patients with mitral stenosis
 Hemodialysis - warfarin is indicated to reduce the risk of stroke in hemodialysis patients

Stroke Risk
 CHA₂DS₂-VASc score (1-9): _____ To calculate the CHA₂DS₂-VASc score, refer to <http://www.cha2ds2-vasc.org/>

Risk Factors	Points
Congestive Heart Failure	1
Hypertension	1
Age 65-74	1
Age ≥ 75 years	2
Diabetes Mellitus	1
Prior stroke or TIA	2
Vascular disease (previous myocardial infarction, arterial disease or aortic plaque)	1
Female	1
	Max 9

[Initiation of Oral Anticoagulant for Atrial Fibrillation Order Set](#)

This is an order set including risk assessment, drug selection, initiation & dosing, labs, patient education & other considerations. Use it as a primary document or to integrate decision-making into your EMR system.

You can also view a [webinar](#) discussing the evolution with authors Dr. Geoff Barnes, Dr. Scott Kaatz, Eva Kline Rogers and Stacy Ellsworth.

[Acute VTE Care Transition Order Set \(Adult\)](#)

This order set may be used for adult patients diagnosed with venous thromboembolism (VTE: deep vein thrombosis, pulmonary embolism) who are ready to be transferred from the hospital or emergency department to outpatient care settings. Use this as a primary document or to integrate decision-making into your EMR system.

Created by the AC Forum, this order set includes factors for drug selection, dosing, DOAC and non-DOAC therapies as well as shared decision-making and kidney and liver function labs and other considerations.

Anticoagulation FORUM PATIENT INFORMATION

Document allergies on approved form and ensure medication reconciliation has been reviewed as per organizational process

Acute VTE Care Transition Order Set (Adult)

Factors Influencing Drug Selection Continued...

SHARED DECISION-MAKING DISCUSSION
 Note: If drug costs are a barrier to filling prescriptions for medication, refer patient to appropriate resources.
 Select all that have been discussed with patient
 Bleeding risk/reversal agents
 Dosing regimen options (e.g. once vs. twice daily)
 Lifestyle factors of drug (e.g. diet, blood draws, activities, taken with meals)
 Out-of-pocket medication cost
 Other (specify): _____

DOAC STANDARD DOSE

DOAC	Apixaban	Rivaroxaban	Edoxaban	Dabigatran
Parenteral lead-in (usually LMWH)	None			
Standard DOAC dose	10 mg PO BID x 7 days, then 5 mg PO BID	15 mg PO BID x 21 days WITH FOOD, then 20 mg PO daily WITH FOOD	60 mg PO daily	150 mg PO BID



Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (COMPASS Trial)
 Thursday, February 8, 12:00 ET

Guest Author & Presenter: John Eikelboom, M.B., B.S.
Moderators: Jack Ansell, MD; Tracy Minichiello, MD; Sara Vazquez, PharmD; Diane Wirth, ANP, CACP

The COMPASS Trial evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. The webinar will focus on emerging evidence with the COMPASS Trial, including the sub-analysis on CAD and PAD.

REGISTER



THSNA Summit 2018
 March 8-10, 2018 | Marriott Marquis | San Diego, California
 Pre-Summit Workshop Day: March 7

comprehensive scientific meeting dedicated to thrombosis and hemostasis issues in San Diego, CA from March 8-10, 2018 with pre-conference sessions held on March 7. Learn more about the [conference](#) and [pre-summit workshops](#).

The hotel block is selling out fast! [Reserve](#) your room by February 13, 2018 to receive our special rate of \$286.00 per night. To reserve 10 rooms or more contact THSNA directly (info@thsna.org).

For reservation by phone, please call: 1-877-622-3056

ThrombosisAdvisorUS Educational Resources and Programs

This new website is intended as an informational resource to help healthcare professionals stay current on relevant clinical information and guidelines, advocacy initiatives, policy updates, latest news, and events. It covers topics related to stroke reduction, vascular protection, and venous protection, and includes direct links to PubMed articles. Visit [ThrombosisAdvisorUS](#) today.

Find out more about Anticoagulation Forum

acforum.org

The Anticoagulation Forum is a multi-disciplinary nonprofit organization of healthcare professionals that will improve the quality of care for patients taking antithrombotic medications

Not a member yet? Join us (it's free!) at acforum.org
Follow us on twitter and Facebook @AnticoagForum



Thank You to Our Newsletter Sponsors

 Bristol-Myers Squibb

 Pfizer



Daiichi-Sankyo

 janssen
PHARMACEUTICAL COMPANIES
of Johnson & Johnson

 **Boehringer
Ingelheim**

 Roche